Lantheus Holdings Price to Free Cash Flow Ratio 2013-2024 | LNTH

Lantheus Holdings current price to free cash flow ratio as of April 08, 2025 is 13.39.

  • Lantheus Holdings average price to free cash flow ratio for 2024 was 13.15, a 20.69% increase from 2023.
  • Lantheus Holdings average price to free cash flow ratio for 2023 was 16.58, a 63.43% decline from 2022.
  • Lantheus Holdings average price to free cash flow ratio for 2022 was 45.34, a 8.18% decline from 2021.

Price to free cash flow ratio can be defined as

Lantheus Holdings Price to Free Cash Flow Ratio 2013-2024 | LNTH

  • Lantheus Holdings average price to free cash flow ratio for 2024 was 13.15, a 20.69% increase from 2023.
  • Lantheus Holdings average price to free cash flow ratio for 2023 was 16.58, a 63.43% decline from 2022.
  • Lantheus Holdings average price to free cash flow ratio for 2022 was 45.34, a 8.18% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$229.2B
Boston Scientific (BSX)$155.9B
Stryker (SYK)$148.3B
EssilorLuxottica (ESLOY)$140.1B
Medtronic (MDT)$111.6B
Lonza Group Ag (LZAGY)$46.2B
Haleon (HLN)$45.2B
GE HealthCare Technologies (GEHC)$42.3B
Agilent Technologies (A)$39.1B
ResMed (RMD)$34.4B
Terumo (TRUMY)$26.6B
Koninklijke Philips (PHG)$23.5B
Zimmer Biomet Holdings (ZBH)$20.6B
Insulet (PODD)$19.9B
Baxter (BAX)$15.7B
Sunny Optical Technology (SNPTF)$11.3B
Smith & Nephew SNATS (SNN)$11.2B
BellRing Brands (BRBR)$9.9B
Demant (WILYY)$7.9B
Bio-Rad Laboratories (BIO)$7.9B
Prestige Consumer Healthcare (PBH)$4.2B
ICU Medical (ICUI)$4B
Envista Holdings (NVST)$3.7B
Perrigo (PRGO)$3.4B
Haemonetics (HAE)$3.2B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.8B
LeMaitre Vascular (LMAT)$2.3B
Neogen (NEOG)$2.2B